{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:51:46Z","timestamp":1785880306576,"version":"3.56.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019657","name":"Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007478","name":"Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.atherosclerosis.2026.120777","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:25:35Z","timestamp":1779679535000},"page":"120777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new era in atherothrombosis"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"L.","family":"Badimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vilahur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mendieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120777_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib2","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1093\/eurheartj\/ehae466","article-title":"European society of cardiology: the 2023 atlas of cardiovascular disease statistics","volume":"45","author":"Timmis","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib4","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1161\/01.CIR.0000041434.28573.0B","article-title":"Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism","volume":"106","author":"Llorente-Cortes","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/01.CIR.0000136032.40666.3D","article-title":"Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells","volume":"110","author":"Llorente-Cortes","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/01.ATV.0000154280.62072.fd","article-title":"LDL receptor-related protein and the vascular wall: implications for atherothrombosis","volume":"25","author":"Llorente-Cortes","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/joim.12296","article-title":"Thrombosis formation on atherosclerotic lesions and plaque rupture","volume":"276","author":"Badimon","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.amjcard.2010.10.028","article-title":"Specific characteristics of sudden death in a mediterranean Spanish population","volume":"107","author":"Subirana","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/0735-1097(94)90657-2","article-title":"Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture","volume":"23","author":"Fernandez-Ortiz","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.95.3.594","article-title":"Tissue factor modulates the thrombogenicity of human atherosclerotic plaques","volume":"95","author":"Toschi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13127","article-title":"Extracellular vesicles in atherothrombosis: from biomarkers and precision medicine to therapeutic targets","volume":"312","author":"Badimon","year":"2022","journal-title":"Immunol Rev"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjmed.2010.07.023","article-title":"Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI","volume":"124","author":"McManus","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00015385.2025.2524233","article-title":"30-year trends in incidence of acute STEMI and NSTEMI in the Belgian province of Luxembourg. A long-term follow-up of the MONICA-BELLUX registry","volume":"80","author":"Gerber","year":"2025","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-087815","article-title":"Why have temporal trends in STEMI and NSTEMI incidence and short-term mortality changed in recent years? A nationwide 35-year cohort study in Iceland","volume":"15","author":"Bjarnadottir","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.711453","article-title":"Plaque erosion: a distinctive pathological mechanism of acute coronary syndrome","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(25)00055-8","article-title":"The lancet commission on rethinking coronary artery disease: moving from ischaemia to atheroma","volume":"405","author":"Zaman","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1432-1327.1998.2520378.x","article-title":"Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells","volume":"252","author":"Vidal","year":"1998","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/156652406778018725","article-title":"Cell biology and lipoproteins in atherosclerosis","volume":"6","author":"Badimon","year":"2006","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100366","article-title":"Intensive lipid lowering agents and coronary atherosclerosis: insights from intravascular imaging","volume":"11","author":"Di Giovanni","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: the PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib25","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib26","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of statins on serial coronary calcification during atheroma progression and regression","volume":"65","author":"Puri","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study","volume":"64","author":"Komukai","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.13577","article-title":"Genetic and molecular architecture of familial hypercholesterolemia","volume":"293","author":"Abifadel","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib33","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib35","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib36","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib37","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib40","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacl.2026.02.006","article-title":"Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis","volume":"20","author":"Kalra","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.114.221242","article-title":"Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement","volume":"353","author":"Henne","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa2511002","article-title":"A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide","volume":"394","author":"Navar","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117354","article-title":"Inclisiran in patients with prior myocardial infarction: a post hoc pooled analysis of the ORION-10 and ORION-11 phase 3 randomised trials","volume":"386","author":"Landmesser","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib46","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib48","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib49","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib50","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehaf266","article-title":"Colchicine in secondary prevention: making sense out of diversity","volume":"46","author":"Pocock","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ehjcvp\/pvab075","article-title":"Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials","volume":"8","author":"Abbate","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib52","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Association of interleukin 6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib54","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-Segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14227910","article-title":"Beyond lipids and platelets: a review of anti-inflammatory strategies in secondary prevention of acute coronary syndromes","volume":"14","author":"Pathangey","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib57","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib60","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial","volume":"315","author":"O'Donoghue","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib61","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","article-title":"Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with angioplasty (COMMA) trial","volume":"108","author":"Granger","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jtcvs.2010.08.035","article-title":"Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials","volume":"142","author":"Smith","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib63","first-page":"1799","article-title":"C-reactive protein and cardiovascular risk in the general population","volume":"47","author":"Kurt","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib64","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American college of cardiology","volume":"87","author":"Mensah","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib65","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib67","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib68","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib69","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1080\/14656566.2025.2601062","article-title":"Lipoprotein (a) - treatments in development","volume":"26","author":"Tomlinson","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2026.120706","article-title":"Association of Lp(a) with coronary plaque burden and high-risk plaque features: a meta-analysis of imaging studies","volume":"415","author":"Sebastian","year":"2026","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib72","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib74","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib75","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib77","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-021-00647-9","article-title":"Prevention of atherosclerosis from childhood","volume":"19","author":"Raitakari","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib78","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib79","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.jacc.2017.10.024","article-title":"Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors","volume":"70","author":"Fernandez-Friera","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib80","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2020.1731","article-title":"Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors","volume":"5","author":"Whelton","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib81","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/CIRCULATIONAHA.106.674143","article-title":"Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the multi-ethnic study of atherosclerosis (MESA)","volume":"115","author":"Kronmal","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib82","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jcmg.2022.03.010","article-title":"Coronary atherosclerosis in an asymptomatic U.S. population: miami heart study at baptist health south Florida","volume":"15","author":"Nasir","year":"2022","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib83","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jacc.2024.06.045","article-title":"Influence of subclinical atherosclerosis burden and progression on mortality","volume":"84","author":"Fuster","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2026.102686","article-title":"Carotid plaque characteristics and their association with cardiovascular risk factors and coronary atherosclerosis in a middle-aged population","author":"Good","year":"2026","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib85","first-page":"79","article-title":"Associations between carotid artery plaque burden, plaque characteristics, and cardiovascular events: the ARIC carotid magnetic resonance imaging study","volume":"6","author":"Brunner","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib86","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1148\/radiol.14131020","article-title":"Carotid artery plaque morphology and composition in relation to incident cardiovascular events: the multi-ethnic study of atherosclerosis (MESA)","volume":"271","author":"Zavodni","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib87","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.114.014310","article-title":"Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (progression of early subclinical atherosclerosis) study","volume":"131","author":"Fernandez-Friera","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib88","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2023.09.814","article-title":"Determinants of progression and regression of subclinical atherosclerosis over 6 years","volume":"82","author":"Mendieta","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib89","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/eurheartj\/ehad361","article-title":"Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study","volume":"44","author":"Sanchez-Cabo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/ATVBAHA.123.320065","article-title":"Eradicating atherosclerotic events by targeting early subclinical disease: it is time to retire the therapeutic paradigm of too much, too late","volume":"44","author":"Williams","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2026.120777_bib91","first-page":"S34","article-title":"Update on lipids, inflammation and atherothrombosis","volume":"105","author":"Badimon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib92","first-page":"60","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease","volume":"1","author":"Badimon","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib93","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jacc.2007.04.082","article-title":"Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy","volume":"50","author":"Kubo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib94","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.292.15.1845","article-title":"Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke","volume":"292","author":"Spagnoli","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurheartj\/ehad720","article-title":"Platelet biology and function: plaque erosion vs. rupture","volume":"45","author":"Baaten","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib96","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1172\/JCI114277","article-title":"Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model","volume":"84","author":"Badimon","year":"1989","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib97","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/ATVBAHA.110.205112","article-title":"Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin","volume":"30","author":"Molins","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib98","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.CIR.90.2.988","article-title":"Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets","volume":"90","author":"Mailhac","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1160\/TH09-11-0771","article-title":"Tissue factor and thrombosis: the clot starts here","volume":"104","author":"Owens","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib100","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/01.CIR.99.14.1780","article-title":"Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions","volume":"99","author":"Badimon","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib101","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cardiores.2006.10.017","article-title":"Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells","volume":"73","author":"Camino-Lopez","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib102","first-page":"303","article-title":"Platelet membrane involvement in blood coagulation","volume":"9","author":"Hemker","year":"1983","journal-title":"Blood Cells (N Y)"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib103","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/eurheartj\/ehu356","article-title":"Changes in thrombus composition and profilin-1 release in acute myocardial infarction","volume":"36","author":"Ramaiola","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib106","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","article-title":"C-Reactive protein in atherothrombosis and angiogenesis","volume":"9","author":"Badimon","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib108","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/jth.12415","article-title":"Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition","volume":"11","author":"de la Torre","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vph.2015.05.001","article-title":"Biological actions of pentraxins","volume":"73","author":"Vilahur","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib110","first-page":"1205","article-title":"Neutrophil extracellular traps (NETs) in cardiovascular diseases: from molecular mechanisms to therapeutic interventions","volume":"81","author":"Natorska","year":"2023","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib111","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/eurheartj\/ehv007","article-title":"Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction","volume":"36","author":"Stakos","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib112","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/eurheartj\/ehv105","article-title":"Neutrophil extracellular traps: a new source of tissue factor in atherothrombosis","volume":"36","author":"Badimon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib113","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehv419","article-title":"Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium","volume":"37","author":"Riegger","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120777_bib114","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fcvm.2017.00077","article-title":"Microvesicles in atherosclerosis and angiogenesis: from bench to bedside and reverse","volume":"4","author":"Badimon","year":"2017","journal-title":"Front Cardiovasc Med"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:36:56Z","timestamp":1785879416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":114,"alternative-id":["S0021915026001437"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120777","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era in atherothrombosis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120777"}}